Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas

Frontiers in Bioscience

Volumn 8, Issue , 2003, Pages

  Krishnan, Sunil ^a   Rao, Ravi D ^b   James, C David ^c   Sarkaria, Jann N ^a,c  

^a Division of Radiation Oncology   (United States)

^b Division of Medical Oncology   (United States)

^c MAYO CLINIC   (United States)

Author keywords

EGFR Inhibitor; Glioma; Radiation; Review

Indexed keywords

4 (3 CHLORO 4 FLUOROANILINO) 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; MONOCLONAL ANTIBODY; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (3 MORPHOLINOPROPOXY) 6 QUINAZOLINYL]ACRYLAMIDE; PKI 116; PROTEIN TYROSINE KINASE INHIBITOR;

ANGIOGENESIS; CORRELATION ANALYSIS; DRUG MECHANISM; DRUG TARGETING; GLIOBLASTOMA; HUMAN; MUTATION; PROTEIN EXPRESSION; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; GENETICS; GLIOMA; IMMUNOLOGY; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY;

ANIMALS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0242276128     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: None     Document Type: Review

References (172)

1. L. M. DeAngelis: Brain tumors. N Engl J Med 344, 114-123. (2001)
2. H. A. Fine, K. B. Dear, J. S. Loeffler, P. M. Black & G. P. Canellos: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71, 2585-2597. (1993)
3. M. D. Prados & V. Levin: Biology and treatment of malignant glioma. Semin Oncol 27, 1-10. (2000)
4. M. Nagane, H. J. Huang & W. K. Cavenee: Causes of drug resistance and novel therapeutic opportunities for the treatment of glioblastoma. Drug Resist Updat 2, 30-37. (1999)
5. L. G. Feun, N. Savaraj & H. J. Landy: Drug resistance in brain tumors. J Neurooncol 20, 165-176 (1994)
6. P. C. Phillips: Antineoplastic drug resistance in brain tumors. Neurol Clin 9, 383-404. (1991)
7. H. Gregory: Isolation and structure of urogastrone and its relationship to epidermal growth factor. Nature 257, 325-327. (1975)
8. J. E. De Larco, R. Reynolds, K. Carlberg, C. Engle & G. J. Todaro: Sarcoma growth factor from mouse sarcoma virus-transformed cells. Purification by binding and elution from epidermal growth factor receptor-rich cells. J Biol Chem 255, 3685-3690. (1980)
9. M. Shoyab, V. L. McDonald, J. G. Bradley & G. J. Todaro: Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci U S A 85, 6528-6532. (1988)
10. S. Higashiyama, J. A. Abraham, J. Miller, J. C. Fiddes & M. Klagsbrun: A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 251, 936-939. (1991)
11. Y. Shing, G. Christofori, D. Hanahan, Y. Ono, R. Sasada, K. Igarashi & J. Folkman: Betacellulin: a mitogen from pancreatic beta cell tumors. Science 259, 1604-1607. (1993)
12. H. Toyoda, T. Komurasaki, Y. Ikeda, M. Yoshimoto & S. Morimoto: Molecular cloning of mouse epiregulin, a novel epidermal growth factor- related protein, expressed in the early stage of development. FEBS Lett 377, 403-407. (1995)
13. P. Stroobant, A. P. Rice, W. J. Gullick, D. J. Cheng, I. M. Kerr & M. D. Waterfield: Purification and characterization of vaccinia virus growth factor. Cell 42, 383-393. (1985)
14. M. M. Feldkamp, N. Lau & A. Guha: Signal transduction pathways and their relevance in human astrocytomas. J Neurooncol 35, 223-248. (1997)
15. C. L. Carpenter & L. C. Cantley: Phosphoinositide kinases. Curr Opin Cell Biol 8, 153-158. (1996)
16. F. G. Kuruvilla & S. L. Schreiber: The PIK-related kinases intercept conventional signaling pathways. Chem Biol 6, R129-136. (1999)
17. H. Harada, J. S. Andersen, M. Mann, N. Terada & S. J. Korsmeyer: p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci U S A 98, 9666-9670. (2001)
18. M. Hidalgo & E. K. Rowinsky: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19, 6680-6686. (2000)
19. A. C. Gingras, B. Raught & N. Sonenberg: Regulation of translation initiation by FRAP/mTOR. Genes Dev 15, 807-826. (2001)
20. J. Downward: Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10, 262-267. (1998)
21. J. E. Perry, M. E. Grossmann & D. J. Tindall: Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line. Prostate 35, 117-124. (1998)
22. S. Gibson, S. Tu, R. Oyer, S. M. Anderson & G. L. Johnson: Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem 274, 17612-17618. (1999)
23. A. Bergmann, M. Tugentman, B. Z. Shilo & H. Steller: Regulation of cell number by MAPK-dependent control of apoptosis: a mechanism for trophic survival signaling. Dev Cell 2, 159-170. (2002)
24. M. Krasilnikov, V. Adler, S. Y. Fuchs, Z. Dong, A. Haimovitz-Friedman, M. Herlyn & Z. Ronai: Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells. MoL Carcinog 24, 64-69. (1999)
25. V. Gire, C. Marshall & D. Wynford-Thomas: PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS. Oncogene 19, 2269-2276. (2000)
26. R. B. Hazan & L. Norton: The epidermal growth factor receptor modulates the interaction of E- cadherin with the actin cytoskeleton. J Biol Chem 273, 9078-9084. (1998)
27. M. A. Adelsman, J. B. McCarthy & Y. Shimizu: Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase. MoL Biol Cell 10, 2861-2878. (1999)
28. B. S. Verbeek, S. S. Adriaansen-Slot, T. M. Vroom, T. Beckers & G. Rijksen: Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett 425, 145-150. (1998)
29. T. Turner, P. Chen, L. J. Goodly & A. Wells: EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp Metastasis 14, 409-418. (1996)
30. L. Damstrup, B. Rude Voldborg, M. Spang-Thomsen, N. Brunner & H. Skovgaard Poulsen: In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor. Br J Cancer 78, 631-640. (1998)
31. R. S. Kerbel, A. Viloria-Petit, F. Okada & J. Rak: Establishing a link between oncogenes and tumor angiogenesis. Mol Med 4, 286-295. (1998)
32. E. C. Holland, W. P. Hively, R. A. DePinho & H. E. Varmus: A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12, 3675-3685. (1998)
33. E. C. Holland, J. Celestino, C. Dai, L. Schaefer, R. E. Sawaya & G. N. Fuller: Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25, 55-57. (2000)
34. T. A. Libermann, H. R. Nusbaum, N. Razon, R. Kris, I. Lax, H. Soreq, N. Whittle, M. D. Waterfield, A. Ullrich & J. Schlessinger: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313, 144-147. (1985)
35. L. Frederick, X. Y. Wang, G. Eley & C. D. James: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60, 1383-1387. (2000)
36. T. A. Libermann, H. R. Nusbaum, N. Razon, R. Kris, I. Lax, H. Soreq, N. Whittle, M. D. Waterfield, A. Ullrich & J. Schlessinger: Amplification and overexpression of the EGF receptor gene in primary human glioblastomas. J Cell Sci Suppl 3, 161-172 (1985)
37. A. J. Wong, S. H. Bigner, D. D. Bigner, K. W. Kinzler, S. R. Hamilton & B. Vogelstein: Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A 84, 6899-6903. (1987)
38. C. Thomas, G. Ely, C. D. James, R. Jenkins, M. Kastan, A. Jedlicka, P. Burger & R. Wharen: Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells. Acta Neuropathol (Berl) 101, 605-615. (2001)
39. S. H. Bigner, P. A. Humphrey, A. J. Wong, B. Vogelstein, J. Mark, H. S. Friedman & D. D. Bigner: Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 50, 8017-8022. (1990)
40. A. J. Wong, J. M. Ruppert, S. H. Bigner, C. H. Grzeschik, P. A. Humphrey, D. S. Bigner & B. Vogelstein: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89, 2965-2969. (1992)
41. A. J. Ekstrand, N. Sugawa, C. D. James & V. P. Collins: Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A 89, 4309-4313. (1992)
42. K. Khazaie, V. Schirrmacher & R. B. Lichtner: EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 12, 255-274. (1993)
43. D. S. Salomon, R. Brandt, F. Ciardiello & N. Normanno: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19, 183-232. (1995)
44. A. J. Ekstrand, C. D. James, W. K. Cavenee, B. Seliger, R. F. Pettersson & V. P. Collins: Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51, 2164-2172. (1991)
45. A. J. Ekstrand, N. Longo, M. L. Hamid, J. J. Olson, L. Liu, V. P. Collins & C. D. James: Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogens 9, 2313-2320. (1994)
46. R. Nishikawa, X. D. Ji, R. C. Harmon, C. S. Lazar, G. N. Gill, W. K. Cavenee & H. J. Huang: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 91, 7727-7731. (1994)
47. D. K. Moscatello, R. B. Montgomery, P. Sundareshan, H. McDanel, M. Y. Wong & A. J. Wong: Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 13, 85-96. (1996)
48. H. S. Huang, M. Nagane, C. K. Klingbeil, H. Lin, R. Nishikawa, X. D. Ji, C. M. Huang, G. N. Gill, H. S. Wiley & W. K. Cavenee: The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272, 2927-2935. (1997)
49. C. T. Chu, K. D. Everiss, C. J. Wikstrand, S. K. Batra, H. J. Kung & D. D. Bigner: Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 324, 855-861. (1997)
50. S. A. Prigent, M. Nagane, H. Lin, I. Huvar, G. R. Boss, J. R. Feramisco, W. K. Cavenee & H. S. Huang: Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras- Shc-Grb2 pathway. J Biol Chem 271, 25639-25645. (1996)
51. D. K. Moscatello, M. Holgado-Madruga, D. R. Emlet, R. B. Montgomery & A. J. Wong: Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 273, 200-206. (1998)
52. S. K. Batra, S. Castelino-Prabhu, C. J. Wikstrand, X. Zhu, P. A. Humphrey, H. S. Friedman & D. D. Bigner: Epidermal growth factor ligand-independent, unregulated, cell- transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 6, 1251-1259. (1995)
53. N. Sugawa, K. Yamamoto, S. Ueda, N. Morita, M. Kita, H. Nishino, S. Fushiki & T. Okabe: Function of aberrant EGFR in malignant gliomas. Brain Tumor Pathol 15, 53-57 (1998)
54. M. E. Berens, M. D. Rief, J. R. Shapiro, D. Haskett, A. Giese, A. Joy & S. W. Coons: Proliferation and motility responses of primary and recurrent gliomas related to changes in epidermal growth factor receptor expression. J Neurooncol 27, 11-22. (1996)
55. M. Nagane, A. Levitzki, A. Gazit, W. K. Cavenee & H. J. Huang: Drug resistance of human glioblastoma cells conferred by a tumor- specific mutant epidermal growth factor receptor through modulation of Bel-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A 95, 5724-5729. (1998)
56. M. Nagane, F. Coufal, H. Lin, O. Bogler, W. K. Cavenee & H. J. Huang: A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56, 5079-5086. (1996)
57. P. Tang, P. A. Steck & W. K. Yung: The autocrine loop of TGF-alpha/EGFR and brain tumors. J Neurooncol 35, 303-314. (1997)
58. B. Westermark, A. Magnusson & C. H. Heldin: Effect of epidermal growth factor on membrane motility and cell locomotion in cultures of human clonal glioma cells. J Neurosci Res 8, 491-507 (1982)
59. M. Lund-Johansen, R. Bjerkvig, P. A. Humphrey, S. H. Bigner, D. D. Bigner & O. D. Laerum: Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. Cancer Res 50, 6039-6044. (1990)
60. M. Lund-Johansen, K. Forsberg, R. Bjerkvig & O. D. Laerum: Effects of growth factors on a human glioma cell line during invasion into rat brain aggregates in culture. Acta Neuropathol 84, 190-197 (1992)
61. M. R. Chicoine, C. L. Madsen & D. L. Silbergeld: Modification of human glioma locomotion in vitro by cytokines EGF, bFGF, PDGFbb, NGF, and TNF alpha. Neurosurgery 36, 1165-1170; discussion 1170-1161. (1995)
62. O. Engebraaten, R. Bjerkvig, P. H. Pedersen & O. D. Laerum: Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro. Int J Cancer 53, 209-214. (1993)
63. P. H. Pedersen, G. O. Ness, O. Engebraaten, R. Bjerkvig, J. R. Lillehaug & O. D. Laerum: Heterogeneous response to the growth factors (EGF, PDGF (bb), TGF-alpha, bFGF, IL-2) on glioma spheroid growth, migration and invasion. Int J Cancer 56, 255-261. (1994)
64. I. F. Dunn, O. Heese & P. M. Black: Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol 50, 121-137. (2000)
65. C. K. Goldman, J. Kim, W. L. Wong, V. King, T. Brock & G. Y. Gillespie: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4, 121-133. (1993)
66. A. Maity, N. Pore, J. Lee, D. Solomon & D. M. O'Rourke: Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 60, 5879-5886. (2000)
67. M. Nister, T. A. Libermann, C. Betsholtz, M. Pettersson, L. Claesson-Welsh, C. H. Heldin, J. Schlessinger & B. Westermark: Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res 48, 3910-3918. (1988)
68. U. Schlegel, P. L. Moots, M. K. Rosenblum, H. T. Thaler & H. M. Furneaux: Expression of transforming growth factor alpha in human gliomas. Oncogene 5, 1839-1842. (1990)
69. H. I. Kornblum, R. J. Hussain, J. M. Bronstein, C. M. Gall, D. C. Lee & K. B. Seroogy: Prenatal ontogeny of the epidermal growth factor receptor and its ligand, transforming growth factor alpha, in the rat brain. J Comp Neurol 380, 243-261. (1997)
70. R. C. Burrows, D. Wancio, P. Levitt & L. Lillien: Response diversity and the timing of progenitor cell maturation are regulated by developmental changes in EGFR expression in the cortex. Neuron 19, 251-267. (1997)
71. K. B. Seroogy, C. M. Gall, D. C. Lee & H. I. Kornblum: Proliferative zones of postnatal rat brain express epidermal growth factor receptor mRNA. Brain Res 670, 157-164. (1995)
72. H. J. Okano, D. W. Pfaff & R. B. Gibbs: Expression of EGFR-, p75NGFR-, and PSTAIR (cdc2)-like immunoreactivity by proliferating cells in the adult rat hippocampal formation and forebrain. Dev Neurosci 18, 199-209 (1996)
73. N. M. Shah, M. A. Marchionni, I. Isaacs, P. Stroobant & D. J. Anderson: Glial growth factor restricts mammalian neural crest stem cells to a glial fate. Cell 77, 349-360. (1994)
74. M. E. Hatten: Riding the glial monorail: a common mechanism for glial-guided neuronal migration in different regions of the developing mammalian brain. Trends Neurosci 13, 179-184. (1990)
75. J. G. Parnavelas & B. Nadarajah: Radial glial cells. are they really glia? Neuron 31, 881-884. (2001)
76. M. K. DeHamer, J. L. Guevara, K. Hannon, B. B. Olwin & A. L. Calof: Genesis of olfactory receptor neurons in vitro: regulation of progenitor cell divisions by fibroblast growth factors. Neuron 13, 1083-1097. (1994)
77. A. L. Calof: Intrinsic and extrinsic factors regulating vertebrate neurogenesis. Curr Opin Neurobiol 5, 19-27. (1995)
78. M. Noble, K. Murray, P. Stroobant, M. D. Waterfield & P. Riddle: Platelet-derived growth factor promotes division and motility and inhibits premature differentiation of the oligodendrocyte/type-2 astrocyte progenitor cell. Nature 333, 560-562. (1988)
79. M. C. Raff, L. E. Lillien, W. D. Richardson, J. F. Burne & M. D. Noble: Platelet-derived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture. Nature 333, 562-565. (1988)
80. S. Temple & M. C. Raff: Clonal analysis of oligodendrocyte development in culture: evidence for a developmental clock that counts cell divisions. Cell 44, 773-779. (1986)
81. R. D. McKinnon, T. Matsui, M. Dubois-Dalcq & S. A. Aaronson: FGF modulates the PDGF-driven pathway of oligodendrocyte development. Neuron 5, 603-614. (1990)
82. O. Bogler, D. Wren, S. C. Barnett, H. Land & M. Noble: Cooperation between two growth factors promotes extended self-renewal and inhibits differentiation of oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells. Proc Natl Acad Sci U S A 87, 6368-6372. (1990)
83. A. L. Vescovi, B. A. Reynolds, D. D. Fraser & S. Weiss: bFGF regulates the proliferative fate of unipotent (neuronal) and bipotent (neuronal/astroglial) EGF-generated CNS progenitor cells. Neuron 11, 951-966. (1993)
84. X. Qian, A. A. Davis, S. K. Goderie & S. Temple: FGF2 concentration regulates the generation of neurons and glia from multipotent cortical stem cells. Neuron 18, 81-93. (1997)
85. R. M. Anchan & T. A. Reh: Transforming growth factor-beta-3 is mitogenic for rat retinal progenitor cells in vitro. J Neurobiol 28, 133-145. (1995)
86. N. K. Mahanthappa & G. A. Schwarting: Peptide growth factor control of olfactory neurogenesis and neuron survival in vitro: roles of EGF and TGF-beta s. Neuron 10, 293-305. (1993)
87. M. F. Mehler, P. C. Mabie, G. Zhu, S. Gokhan & J. A. Kessler: Developmental changes in progenitor cell responsiveness to bone morphogenetic proteins differentially modulate progressive CNS lineage fate. Dev Neurosci 22, 74-85 (2000)
88. X. Lin & R. F. Bulleit: Insulin-like growth factor I (IGF-I) is a critical trophic factor for developing cerebellar granule cells. Brain Res Dev Brain Res 99, 234-242. (1997)
89. S. Fuhrmann, S. Heller, H. Rohrer & H. D. Hofmann: A transient role for ciliary neurotrophic factor in chick photoreceptor development. J Neurobiol 37, 672-683. (1998)
90. S. A. Koblar, A. M. Turnley, B. J. Classon, K. L. Reid, C. B. Ware, S. S. Cheema, M. Murphy & P. F. Bartlett: Neural precursor differentiation into astrocytes requires signaling through the leukemia inhibitory factor receptor. Proc Natl Acad Sci U S A 95, 3178-3181. (1998)
91. S. B. Noonberg & C. C. Benz: Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 59, 753-767. (2000)
92. J. Mendelsohn: The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 8, 3-9. (2001)
93. T. Kawamoto, J. D. Sato, A. Le, J. Polikoff, G. H. Sato & J. Mendelsohn: Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A 80, 1337-1341. (1983)
94. G. N. Gill, T. Kawamoto, C. Cochet, A. Le, J. D. Sato, H. Masui, C. McLeod & J. Mendelsohn: Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259, 7755-7760. (1984)
95. P. Perrotte, T. Matsumoto, K. Inoue, H. Kuniyasu, B. Y. Eve, D. J. Hicklin, R. Radinsky & C. P. Dinney: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5, 257-265. (1999)
96. A. M. Petit, J. Rak, M. C. Hung, P. Rockwell, N. Goldstein, B. Fendly & R. S. Kerbel: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151, 1523-1530. (1997)
97. J. H. Sampson, L. E. Crotty, S. Lee, G. E. Archer, D. M. Ashley, C. J. Wikstrand, L. P. Hale, C. Small, G. Dranoff, A. H. Friedman, H. S. Friedman & D. D. Bigner: Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 97, 7503-7508. (2000)
98. K. Mishima, T. G. Johns, R. B. Luwor, A. M. Scott, E. Stocken, A. A. Jungbluth, X. D. Ji, P. Suvarna, J. R. Voland, L. J. Old, H. J. Huang & W. K. Cavenee: Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 61, 5349-5354. (2001)
99. R. B. Luwor, T. G. Johns, C. Murone, H. J. Huang, W. K. Cavenee, G. Ritter, L. J. Old, A. W. Burgess & A. M. Scott: Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 61, 5355-5361. (2001)
100. D. R. Negri, E. Tosi, O. Valota, S. Ferrini, A. Cambiaggi, S. Sforzini, A. Silvani, P. A. Ruffini, M. I. Colnaghi & S. Canevari: In vitro and in vivo stability and anti-tumour efficacy of an anti- EGFR/anti-CD3 F(ab′)2 bispecific monoclonal antibody. Br J Cancer 72, 928-933. (1995)
101. M. Azemar, M. Schmidt, F. Arlt, P. Kennel, B. Brandt, A. Papadimitriou, B. Groner & W. Wels: Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int J Cancer 86, 269-275. (2000)
102. M. Schmidt, M. Maurer-Gebhard, B. Groner, G. Kohler, G. Brochmann-Santos & W. Wels: Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors. Oncogene 18, 1711-1721. (1999)
103. F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Pomatico, S. De Placido, A. R. Bianco & G. Tortora: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor- selective tyrosine kinase inhibitor. Clin Cancer Res 6, 2053-2063. (2000)
104. V. A. Pollack, D. M. Savage, D. A. Baker, K. E. Tsaparikos, D. E. Sloan, J. D. Moyer, E. G. Barbacci, L. R. Pustilnik, T. A. Smolarek, J. A. Davis, M. P. Vaidya, L. D. Arnold, J. L. Doty, K. K. Iwata & M. J. Morin: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291, 739-748. (1999)
105. J. B. Smaill, G. W. Rewcastle, J. A. Loo, K. D. Greis, O. H. Chan, E. L. Reyner, E. Lipka, H. D. Showalter, P. W. Vincent, W. L. Elliott & W. A. Denny: Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazoline- and 4- (Phenylamino)pyrido. J Med Chem 43, 1380-1397. (2000)
106. C. J. Bruns, C. C. Solorzano, M. T. Harbison, S. Ozawa, R. Tsan, D. Fan, J. Abbruzzese, P. Traxler, E. Buchdunger, R. Radinsky & I. J. Fidler: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60, 2926-2935. (2000)
107. L. K. Shawver, D. Slamon & A. Ullrich: Smart drugs: Tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1, 117-123. (2002)
108. Y. Han, C. G. Caday, A. Nanda, W. K. Cavenee & H. J. Huang: Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res 56, 3859-3861. (1996)
109. P. D. Ryan & B. A. Chabner: On receptor inhibitors and chemotherapy. Clin Cancer Res 6, 4607-4609. (2000)
110. W. Hamel & M. Westphal: Growth factors in gliomas revisited. Acta Neurochir 142, 113-137 (2000)
111. A. Chakravarti, J. S. Loeffler & N. J. Dyson: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62, 200-207. (2002)
112. M. D. Walker, E. Alexander, Jr., W. E. Hunt, C. S. MacCarty, M. S. Mahaley, Jr., J. Mealey, Jr., H. A. Norrell, G. Owens, J. Ransohoff, C. B. Wilson, E. A. Gehan & T. A. Strike: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49, 333-343. (1978)
113. F. G. Barker, 2nd, M. L. Simmons, S. M. Chang, M. D. Prados, D. A. Larson, P. K. Sneed, W. M. Wara, M. S. Berger, P. Chen, M. A. Israel & K. D. Aldape: EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51, 410-418. (2001)
114. P. M. Harari & S. M. Huang: Modulation of molecular targets to enhance radiation. Clin Cancer Res 6, 323-325. (2000)
115. T. Akimoto, N. R. Hunter, L. Buchmiller, K. Mason, K. K. Ang & L. Milas: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5, 2884-2890. (1999)
116. M. Maurizi, G. Almadori, G. Ferrandina, M. Distefano, M. E. Romanini, G. Cadoni, P. Benedetti-Panici, G. Paludetti, G. Scambia & S. Mancuso: Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 74, 1253-1257. (1996)
117. J. S. Smith, I. Tachibana, S. M. Passe, B. K. Huntley, T. J. Borell, N. Iturria, J. R. O'Fallon, P. L. Schaefer, B. W. Scheithauer, C. D. James, J. C. Buckner & R. B. Jenkins: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93, 1246-1256. (2001)
118. M. R. Pillai, P. G. Jayaprakash & M. K. Nair: Tumour-proliferative fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix. J Cancer Res Clin Oncol 124, 456-461 (1998)
119. A. Zhu, J. Shaeffer, S. Leslie, P. Kolm & A. M. El-Mahdi: Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys 34, 809-815. (1996)
120. B. D. Kavanagh, P. S. Lin, P. Chen & R. K. Schmidt-Ullrich: Radiation-induced enhanced proliferation of human squamous cancer cells in vitro: a release from inhibition by epidermal growth factor. Clin Cancer Res 1, 1557-1562. (1995)
121. R. K. Schmidt-Ullrich, K. Valerie, P. B. Fogleman & J. Walters: Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat Res 145, 81-85. (1996)
122. N. Balaban, J. Moni, M. Shannon, L. Dang, E. Murphy & T. Goldkorn: The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. Biochim Biophys Acta 1314, 147-156. (1996)
123. T. Goldkorn, N. Balaban, M. Shannon & K. Matsukuma: EGF receptor phosphorylation is affected by ionizing radiation. Biochim Biophys Acta 1358, 289-299. (1997)
124. R. K. Schmidt-Ullrich, R. B. Mikkelsen, P. Dent, D. G. Todd, K. Valerie, B. D. Kavanagh, J. N. Contessa, W. K. Rorrer & P. B. Chen: Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15, 1191-1197. (1997)
125. P. Dent, D. B. Reardon, J. S. Park, G. Bowers, C. Logsdon, K. Valerie & R. Schmidt-Ullrich: Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10, 2493-2506. (1999)
126. A. Knebel, H. J. Rahmsdorf, A. Ullrich & P. Herrlich: Dephosphorylation of receptor tyrosine kinases as target of regulation by radiation, oxidants or alkylating agents. Embo J 15, 5314-5325. (1996)
127. C. Wild-Bode, M. Weller, A. Rimner, J. Dichgans & W. Wick: Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 61, 2744-2750. (2001)
128. R. K. Schmidt-Ullrich, P. Dent, S. Grant, R. B. Mikkelsen & K. Valerie: Signal transduction and cellular radiation responses. Radiat Res 153, 245-257. (2000)
129. M. N. Saleh, K. P. Raisch, M. A. Stackhouse, W. E. Grizzle, J. A. Bonner, M. S. Mayo, H. G. Kim, R. F. Meredith, R. H. Wheeler & D. J. Buchsbaum: Combined modality therapy of A431 human epidermoid cancer using anti- EGFr antibody C225 and radiation. Cancer Biother Radiopharm 14, 451-463. (1999)
130. S. M. Huang, J. M. Bock & P. M. Harari: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59, 1935-1940. (1999)
131. P. M. Harari & S. M. Huang: Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 49, 427-433. (2001)
132. C. Bianco, R. Bianco, G. Tortora, V. Damiano, P. Guerrieri, P. Montemaggi, J. Mendelsohn, S. De Placido, A. R. Bianco & F. Ciardiello: Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 6, 4343-4350. (2000)
133. S. M. Huang & P. M. Harari: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6, 2166-2174. (2000)
134. L. Milas, K. Mason, N. Hunter, S. Petersen, M. Yamakawa, K. Ang, J. Mendelsohn & Z. Fan: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6, 701-708. (2000)
135. S. Nasu, K. K. Ang, Z. Fan & L. Milas: C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 51, 474-477. (2001)
136. D. Raben, D. J. Buchsbaum, G. Y. Gillespie & et. al.: Treatment of human intracranial gliomas with chimeric monoclonal antibody against epidermal growth factor receptor increases survival of nude mice when treated concurrently with irradiation. Proc Am Assoc Cancer 40, A1224 (abst) (1999)
137. M. Hagan, L. Wang, J. R. Hanley, J. S. Park & P. Dent: Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest. Radiat Res 153, 371-383. (2000)
138. D. Raben, B. A. Helfrich, D. Chan, G. Johnson & P. A. Bunn, Jr.: ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 29, 37-46. (2002)
139. G. Lammering, T. H. Hewit, W. T. Hawkins, J. N. Contessa, D. B. Reardon, P. S. Lin, K. Valerie, P. Dent, R. B. Mikkelsen & R. K. Schmidt-Ullrich: Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst 93, 921-929. (2001)
140. E. J. Hall: Repair of radiation damage and the dose-rate effect. In: Radiobiology for the radiologist. Eds: E. J. Hall. Lippincott Williams & wilkins, Philadelphia 67-90 (2000)
141. U. Kasid, A. Pfeifer, T. Brennan, M. Beckett, R. R. Weichselbaum, A. Dritschilo & G. E. Mark: Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science 243, 1354-1356. (1989)
142. A. K. Gupta, V. J. Bakanauskas, G. J. Cerniglia, Y. Cheng, E. J. Bernhard, R. J. Muschel & W. G. McKenna: The Ras radiation resistance pathway. Cancer Res 61, 4278-4282. (2001)
143. K. F. Pirollo, R. Garner, S. Y. Yuan, L. Li, W. A. Blattner & E. H. Chang: raf involvement in the simultaneous genetic transfer of the radioresistant and transforming phenotypes. Int J Radiat Biol 55, 783-796. (1989)
144. W. G. McKenna, M. C. Weiss, V. J. Bakanauskas, H. Sandler, M. L. Kelsten, J. Biaglow, S. W. Tuttle, B. Endlich, C. C. Ling & R. J. Muschel: The role of the H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys 18, 849-859. (1990)
145. H. A. Jones, S. M. Hahn, E. Bernhard & W. G. McKenna: Ras inhibitors and radiation therapy. Semin Radiat Oncol 11, 328-337. (2001)
146. D. Bandyopadhyay, M. Mandal, L. Adam, J. Mendelsohn & R. Kumar: Physical interaction between epidermal growth factor receptor and DNA- dependent protein kinase in mammalian cells. J Biol Chem 273, 1568-1573. (1998)
147. E. J. Hall: Time, dose, and fractionation in radiotherapy. In: Radiobiology for the radiologist. Eds: E. J. Hall. Lippincott Williams & Wilkins, Philadelphia 397-418 (2000)
148. J. F. Fowler & M. J. Lindstrom: Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 23, 457-467 (1992)
149. D. G. Petereit, J. N. Sarkaria, R. Chappell, J. F. Fowler, T. J. Hartmann, T. J. Kinsella, J. A. Stitt, B. R. Thomadsen & D. A. Buchler: The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 32, 1301-1307. (1995)
150. A. Fyles, T. J. Keane, M. Barton & J. Simm: The effect of treatment duration in the local control of cervix cancer. Radiother Oncol 25, 273-279. (1992)
151. R. M. Lanciano, T. F. Pajak, K. Martz & G. E. Hanks: The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. Int J Radiat Oncol Biol Phys 25, 391-397. (1993)
152. H. R. Withers, J. M. Taylor & B. Maciejewski: The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27, 131-146 (1988)
153. W. Dorr, H. Emmendorfer & M. Weber-Frisch: Tissue kinetics in mouse tongue mucosa during daily fractionated radiotherapy. Cell Prolif 29, 495-504. (1996)
154. K. Liu, M. Kasper & K. R. Trott: Changes in keratinocyte differentiation during accelerated repopulation of the irradiated mouse epidermis. Int J Radiat Biol 69, 763-769. (1996)
155. J. N. Sarkaria, J. F. Fowler, M. J. Lindstrom, V. C. Jordan & R. T. Mulcahy: The decreased influence of overall treatment time on the response of human breast tumor xenografts following prolongation of the potential doubling time (Tpot). Int J Radiat Oncol Biol Phys 31, 833-840. (1995)
156. R. K. Schmidt-Ullrich, J. N. Contessa, P. Dent, R. B. Mikkelsen, K. Valerie, D. B. Reardon, G. Bowers & P. S. Lin: Molecular mechanisms of radiation-induced accelerated repopulation. Radiat Oncol Investig 7, 321-330 (1999)
157. C. Hess, V. Vuong, I. Hegyi, O. Riesterer, J. Wood, D. Fabbro, C. Glanzmann, S. Bodis & M. Pruschy: Effect of VEGF receptor inhibitor PTK787/ZK222584 (correction of ZK222548) combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 85, 2010-2016. (2001)
158. S. Ning, D. Laird, J. M. Cherrington & S. J. Knox: The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 157, 45-51. (2002)
159. L. Geng, E. Donnelly, G. McMahon, P. C. Lin, E. Sierra-Rivera, H. Oshinka & D. E. Hallahan: Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61, 2413-2419. (2001)
160. E. L. Lund, L. Bastholm & P. E. Kristjansen: Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 6, 971-978. (2000)
161. D. H. Gorski, M. A. Beckett, N. T. Jaskowiak, D. P. Calvin, H. J. Mauceri, R. M. Salloum, S. Seetharam, A. Koons, D. M. Hari, D. W. Kufe & R. R. Weichselbaum: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59, 3374-3378. (1999)
162. D. H. Gorski, H. J. Mauceri, R. M. Salloum, S. Gately, S. Hellman, M. A. Beckett, V. P. Sukhatme, G. A. Soff, D. W. Kufe & R. R. Weichselbaum: Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 58, 5686-5689. (1998)
163. N. M. Mazure, E. Y. Chen, K. R. Laderoute & A. J. Giaccia: Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras- transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90, 3322-3331. (1997)
164. H. Zhong, K. Chiles, D. Feldser, E. Laughner, C. Hanrahan, M. M. Georgescu, J. W. Simons & G. L. Semenza: Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60, 1541-1545. (2000)
165. A. L. Harris: Hypoxia - a key regulatory factor in tumour growth. Nature Rev Cancer 2, 38-47. (2002)
166. M. C. Papadopoulos, S. Saadoun, D. C. Davies & B. A. Bell: Emerging molecular mechanisms of brain tumour oedema. Br J Neurosurg 15, 101-108. (2001)
167. M. R. Machein & K. H. Plate: VEGF in brain tumors. J Neurooncol 50, 109-120. (2000)
168. M. R. Machein, J. Kullmer, B. L. Fiebich, K. H. Plate & P. C. Warnke: Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors. Neurosurgery 44, 732-740; discussion 740-731. (1999)
169. K. H. Plate & P. C. Warnke: Vascular endothelial growth factor. J Neurooncol 35, 365-372. (1997)
170. E. J. Hall: The oxygen effect and reoxygenation. In: Radiobiology for the radiologist. 91-111 (2000)
171. E. J. Hall: Radiosensitivity and cell age in the mitotic cycle. In: Radiobiology for the radiologist. Eds: E. J. Hall. Philadelphia 51-66 (2000)
172. J. A. Bonner, K. P. Raisch, H. Q. Trummell, F. Robert, R. F. Meredith, S. A. Spencer, D. J. Buchsbaum, M. N. Saleh, M. A. Stackhouse, A. F. LoBuglio, G. E. Peters, W. R. Carroll & H. W. Waksal: Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 18, 47S-53S. (2000)